Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Bariatric procedures for the management of severe obesity: Descriptions

Robert B Lim, MD, FACS, COL, MC, USA
Section Editor
Daniel Jones, MD
Deputy Editor
Wenliang Chen, MD, PhD


Operations for weight loss include a combination of volume restrictive and nutrient malabsorptive procedures that affect satiety, absorption, and insulin sensitivity via hormonal or enteric derived factors, in conjunction with behavior modification to achieve and sustain weight loss.

A consultation with a multidisciplinary bariatric team provides extensive education on nutrition, psychological deterrents, and lifestyle modification to determine if an obese patient is a candidate for a surgical weight loss procedure. Proper bariatric care also includes lifelong surveillance. A reliable bariatric program will provide a comprehensive information session for potential surgical candidates that will detail realistic outcomes from weight loss surgery including morbidities and mortalities [1].

This topic will review the contemporary, investigational, revisional, and obsolete bariatric procedures offered to obese patients with a body mass index (BMI) of greater than or equal to 40 kg/m2, a BMI of 35 to 39.9 kg/m2 with an obesity-related comorbidity (eg, diabetes, hypertension, gastroesophageal reflux disease, some osteoarthritis), or a BMI of 30 to 34.9 kg/m2 with difficult-to-control type II diabetes mellitus or dysmetabolic syndrome X.

Indications, preoperative preparation, postoperative management, complications, and outcomes of bariatric surgical procedures are described in the following topics:

(See "Bariatric surgery: Postoperative and long-term management of the uncomplicated patient".)


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Jul 20, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Lim RB, Blackburn GL, Jones DB. Benchmarking best practices in weight loss surgery. Curr Probl Surg 2010; 47:79.
  2. Buchwald H, Oien DM. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013; 23:427.
  3. Lomanto D, Lee WJ, Goel R, et al. Bariatric surgery in Asia in the last 5 years (2005-2009). Obes Surg 2012; 22:502.
  4. American Society for Metabolic and Bariatric Surgery (2009) Fact Sheet: Metabolic & Bariatric Surgery. Available online at: www.asbs.org/Newsite07/media/asbs_presskit.htm (Accessed on January 28, 2009).
  5. Nguyen NT, Masoomi H, Magno CP, et al. Trends in use of bariatric surgery, 2003-2008. J Am Coll Surg 2011; 213:261.
  6. Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSQIP), a joint program of the American College of Surgeons and the American Society for Metabolic and Bariatric Surgery. www.mbsaqip.org/ (Accessed on May 23, 2013).
  7. Tritos NA, Mun E, Bertkau A, et al. Serum ghrelin levels in response to glucose load in obese subjects post-gastric bypass surgery. Obes Res 2003; 11:919.
  8. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346:1623.
  9. Korner J, Bessler M, Cirilo LJ, et al. Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab 2005; 90:359.
  10. Karamanakos SN, Vagenas K, Kalfarentzos F, Alexandrides TK. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg 2008; 247:401.
  11. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg 2006; 243:108.
  12. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 2004; 240:236.
  13. Roth CL, Reinehr T, Schernthaner GH, et al. Ghrelin and obestatin levels in severely obese women before and after weight loss after Roux-en-Y gastric bypass surgery. Obes Surg 2009; 19:29.
  14. Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007; 132:2253.
  15. Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Registry. Am J Surg 2006; 192:657.
  16. ASMBS. The Story of Surgery for Obesity. Brief History and Summary of Bariatric Surgery. Chapter 3: Gastric Bypass. Available online at: www.asbs.org/html/patients/bypass.html (Accessed on April 1, 2009).
  17. Austrheim-Smith I, Brethauer S, Rogula T, Wolfe B. Evolution of bariatric minimally invasive surgery. In: Schauer P, Schirmer B, Brethauer S, eds. Minimally invasive bariatric surgery. 2007:17.
  18. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 1987; 205:613.
  19. Kellum JM, Kuemmerle JF, O'Dorisio TM, et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg 1990; 211:763.
  20. Brolin RE, LaMarca LB, Kenler HA, Cody RP. Malabsorptive gastric bypass in patients with superobesity. J Gastrointest Surg 2002; 6:195.
  21. Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg 2012; 22:1084.
  22. Nelson DW, Blair KS, Martin MJ. Analysis of obesity-related outcomes and bariatric failure rates with the duodenal switch vs gastric bypass for morbid obesity. Arch Surg 2012; 147:847.
  23. Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk super-obese patient. Obes Surg 2004; 14:492.
  24. Regan JP, Inabnet WB, Gagner M, Pomp A. Early experience with two-stage laparoscopic Roux-en-Y gastric bypass as an alternative in the super-super obese patient. Obes Surg 2003; 13:861.
  25. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers (Accessed on June 28, 2016).
  26. Felberbauer FX, Langer F, Shakeri-Manesch S, et al. Laparoscopic sleeve gastrectomy as an isolated bariatric procedure: intermediate-term results from a large series in three Austrian centers. Obes Surg 2008; 18:814.
  27. Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg 2005; 15:1469.
  28. Deitel M, Gagner M, Erickson AL, Crosby RD. Third International Summit: Current status of sleeve gastrectomy. Surg Obes Relat Dis 2011; 7:749.
  29. Baumann T, Kuesters S, Grueneberger J, et al. Time-resolved MRI after ingestion of liquids reveals motility changes after laparoscopic sleeve gastrectomy--preliminary results. Obes Surg 2011; 21:95.
  30. Braghetto I, Davanzo C, Korn O, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg 2009; 19:1515.
  31. Gagner M, Deitel M, Kalberer TL, et al. The Second International Consensus Summit for Sleeve Gastrectomy, March 19-21, 2009. Surg Obes Relat Dis 2009; 5:476.
  32. Ramón JM, Salvans S, Crous X, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg 2012; 16:1116.
  33. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366:1567.
  34. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 2011; 254:410.
  35. Cottam D, Qureshi FG, Mattar SG, et al. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc 2006; 20:859.
  36. van Rutte PW, Smulders JF, de Zoete JP, Nienhuijs SW. Outcome of sleeve gastrectomy as a primary bariatric procedure. Br J Surg 2014; 101:661.
  37. O'Brien PE, MacDonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257:87.
  38. Puzziferri N, Roshek TB 3rd, Mayo HG, et al. Long-term follow-up after bariatric surgery: a systematic review. JAMA 2014; 312:934.
  39. Belachew M, Legrand M, Vincenti V V, et al. Laparoscopic Placement of Adjustable Silicone Gastric Band in the Treatment of Morbid Obesity: How to Do It. Obes Surg 1995; 5:66.
  40. O'Brien PE, Brown WA, Smith A, et al. Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity. Br J Surg 1999; 86:113.
  41. O'Brien PE, Dixon JB. Lap-band: outcomes and results. J Laparoendosc Adv Surg Tech A 2003; 13:265.
  42. FDA Trial Summary of Safety and Effectiveness Data: The Lap-Band Adjustable Gastric Banding System (P000008). Available online at www.accessdata.fda.gov/cdrh_docs/pdf/P000008b.pdf (Accessed on June 17, 2010).
  43. Sanchez H, Cabrera A, Cabrera K, et al. Laparoscopic Roux-en-Y gastric bypass as a revision procedure after restrictive bariatric surgery. Obes Surg 2008; 18:1539.
  44. O'Brien PE. Laparoscopic adjustable gastric banding: a real option for a real problem. ANZ J Surg 2003; 73:562.
  45. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998; 8:267.
  46. Marceau P, Hould FS, Simard S, et al. Biliopancreatic diversion with duodenal switch. World J Surg 1998; 22:947.
  47. Ren CJ, Patterson E, Gagner M. Early results of laparoscopic biliopancreatic diversion with duodenal switch: a case series of 40 consecutive patients. Obes Surg 2000; 10:514.
  48. Baltasar A, Bou R, Miró J, et al. Laparoscopic biliopancreatic diversion with duodenal switch: technique and initial experience. Obes Surg 2002; 12:245.
  49. Kotidis EV, Koliakos G, Papavramidis TS, Papavramidis ST. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg 2006; 16:554.
  50. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc 2005; 61:19.
  51. Roman S, Napoléon B, Mion F, et al. Intragastric balloon for "non-morbid" obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg 2004; 14:539.
  52. Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg 2004; 14:991.
  53. Busetto L, Segato G, De Luca M, et al. Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study. Obes Surg 2004; 14:671.
  54. Zerrweck C, Maunoury V, Caiazzo R, et al. Preoperative weight loss with intragastric balloon decreases the risk of significant adverse outcomes of laparoscopic gastric bypass in super-super obese patients. Obes Surg 2012; 22:777.
  55. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm456296.htm (Accessed on September 10, 2015).
  56. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm457416.htm (Accessed on February 24, 2016).
  57. Ponce J, Woodman G, Swain J, et al. The REDUCE pivotal trial: a prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity. Surg Obes Relat Dis 2015; 11:874.
  58. Genco A, Bruni T, Doldi SB, et al. BioEnterics Intragastric Balloon: The Italian Experience with 2,515 Patients. Obes Surg 2005; 15:1161.
  59. Kotzampassi K, Grosomanidis V, Papakostas P, et al. 500 intragastric balloons: what happens 5 years thereafter? Obes Surg 2012; 22:896.
  60. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430223.htm (Accessed on September 17, 2015).
  61. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm430696.htm (Accessed on September 14, 2015).
  62. Kral JG, Paez W, Wolfe BM. Vagal nerve function in obesity: therapeutic implications. World J Surg 2009; 33:1995.
  63. Ikramuddin S, Blackstone RP, Brancatisano A, et al. Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial. JAMA 2014; 312:915.
  64. Sullivan S, Stein R, Jonnalagadda S, et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013; 145:1245.
  65. Wang W, Wei PL, Lee YC, et al. Short-term results of laparoscopic mini-gastric bypass. Obes Surg 2005; 15:648.
  66. Noun R, Skaff J, Riachi E, et al. One thousand consecutive mini-gastric bypass: short- and long-term outcome. Obes Surg 2012; 22:697.
  67. Noun R, Riachi E, Zeidan S, et al. Mini-gastric bypass by mini-laparotomy: a cost-effective alternative in the laparoscopic era. Obes Surg 2007; 17:1482.
  68. Rutledge R. The mini-gastric bypass: experience with the first 1,274 cases. Obes Surg 2001; 11:276.
  69. Lee WJ, Ser KH, Lee YC, et al. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg 2012; 22:1827.
  70. Fong AK, Wong SK, Lam CC, Ng EK. Ghrelin level and weight loss after laparoscopic sleeve gastrectomy and gastric mini-bypass for Prader-Willi syndrome in Chinese. Obes Surg 2012; 22:1742.
  71. Dang H, Arias E, Szomstein S, Rosenthal R. Laparoscopic conversion of distal mini-gastric bypass to proximal Roux-en-Y gastric bypass for malnutrition: case report and review of the literature. Surg Obes Relat Dis 2009; 5:383.
  72. Bruzzi M, Rau C, Voron T, et al. Single anastomosis or mini-gastric bypass: long-term results and quality of life after a 5-year follow-up. Surg Obes Relat Dis 2015; 11:321.
  73. Lee WJ, Chong K, Lin YH, et al. Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg 2014; 24:1552.
  74. Majumder S, Birk J. A review of the current status of endoluminal therapy as a primary approach to obesity management. Surg Endosc 2013; 27:2305.
  75. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc 2011; 74:1248.
  76. Fogel R, De Fogel J, Bonilla Y, De La Fuente R. Clinical experience of transoral suturing for an endoluminal vertical gastroplasty: 1-year follow-up in 64 patients. Gastrointest Endosc 2008; 68:51.
  77. Brethauer SA, Chand B, Schauer PR, Thompson CC. Transoral gastric volume reduction as intervention for weight management: 12-month follow-up of TRIM trial. Surg Obes Relat Dis 2012; 8:296.
  78. Sandler BJ, Rumbaut R, Swain CP, et al. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc 2011; 25:3028.
  79. Horgan S, Jacobsen G, Weiss GD, et al. Incisionless revision of post-Roux-en-Y bypass stomal and pouch dilation: multicenter registry results. Surg Obes Relat Dis 2010; 6:290.
  80. Ryou M, Mullady DK, Lautz DB, Thompson CC. Pilot study evaluating technical feasibility and early outcomes of second-generation endosurgical platform for treatment of weight regain after gastric bypass surgery. Surg Obes Relat Dis 2009; 5:450.
  81. Golomb I, Ben David M, Glass A, et al. Long-term Metabolic Effects of Laparoscopic Sleeve Gastrectomy. JAMA Surg 2015; 150:1051.
  82. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996; 119:261.
  83. Payne JH, DeWind LT. Surgical treatment of obesity. Am J Surg 1969; 118:141.
  84. Kamiński JP, Maker VK, Maker AV. Management of patients with abdominal malignancy after remote jejunoileal bypass: surgical considerations decades later. J Am Coll Surg 2013; 217:929.
  85. Halverson JD, Wise L, Wazna MF, Ballinger WF. Jejunoileal bypass for morbid obesity. A critical appraisal. Am J Med 1978; 64:461.
  86. Clayman RV, Williams RD. Oxalate urolithiasis following jejunoileal bypass. Surg Clin North Am 1979; 59:1071.
  87. Kroyer JM, Talbert WM Jr. Morphologic liver changes in intestinal bypass patients. Am J Surg 1980; 139:855.
  88. Griffen WO Jr, Bivins BA, Bell RM. The decline and fall of the jejunoileal bypass. Surg Gynecol Obstet 1983; 157:301.
  89. Deitel M, Shahi B, Anand PK, et al. Long-term Outcome in a Series of Jejunoileal Bypass Patients. Obes Surg 1993; 3:247.
  90. Miller K, Pump A, Hell E. Vertical banded gastroplasty versus adjustable gastric banding: prospective long-term follow-up study. Surg Obes Relat Dis 2007; 3:84.
  91. Balsiger BM, Poggio JL, Mai J, et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000; 4:598.
  92. Nightengale ML, Sarr MG, Kelly KA, et al. Prospective evaluation of vertical banded gastroplasty as the primary operation for morbid obesity. Mayo Clin Proc 1991; 66:773.
  93. Sugerman HJ, Londrey GL, Kellum JM, et al. Weight loss with vertical banded gastroplasty and Roux-Y gastric bypass for morbid obesity with selective versus random assignment. Am J Surg 1989; 157:93.
  94. Benotti PN, Forse RA. Safety and long-term efficacy of revisional surgery in severe obesity. Am J Surg 1996; 172:232.
  95. van Gemert WG, van Wersch MM, Greve JW, Soeters PB. Revisional surgery after failed vertical banded gastroplasty: restoration of vertical banded gastroplasty or conversion to gastric bypass. Obes Surg 1998; 8:21.
  96. Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic Gastric Bypass, Roux-en-Y: Preliminary Report of Five Cases. Obes Surg 1994; 4:353.
  97. Farrell TM, Haggerty SP, Overby DW, et al. Clinical application of laparoscopic bariatric surgery: an evidence-based review. Surg Endosc 2009; 23:930.
  98. Schauer P, Ikramuddin S, Hamad G, Gourash W. The learning curve for laparoscopic Roux-en-Y gastric bypass is 100 cases. Surg Endosc 2003; 17:212.
  99. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001; 120:669.
  100. Guedea ME, Arribas del Amo D, Solanas JA, et al. Results of biliopancreatic diversion after five years. Obes Surg 2004; 14:766.
  101. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982; 117:701.
  102. Sugerman HJ, Kellum JM Jr, DeMaria EJ, Reines HD. Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg 1996; 171:263.
Topic Outline